Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy

This study has been completed.
Information provided by:
Uppsala University Identifier:
First received: October 16, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
SPECT was performed in 51 patients after cytoreductive surgery in combination with intraperitoneal chemotherapy. The detected volume was compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses that could be performed without further surgical intervention. SPECT data was found to predict feasibility of sequential postoperative intraperitoneal chemotherapy.

Peritoneal Carcinomatosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Single-photon Emission Computed Tomography for Prediction of Treatment Results in Sequential Intraperitoneal Chemotherapy at Peritoneal Carcinomatosis

Further study details as provided by Uppsala University:

Primary Outcome Measures:
  • Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses

Secondary Outcome Measures:
  • The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables

Enrollment: 51
Study Start Date: May 1991
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Peritoneal carcinomatosis
Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment


Ages Eligible for Study:   14 Years to 74 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who had undergone cytoreductive surgery and intraperitoneal chemotherapy (SPIC) at the Dept of Surgical Sciences, Uppsala University Hospital in the time period between May 1991 and August 2004.

Inclusion Criteria:

  • Cytoreductive surgery and intraperitoneal chemotherapy
  • Single-Photon Emission Computed Tomography (SPECT) before the second course of treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00997633

Dept of Surgical Sciences, Section of Surgery
S-751 85 Uppsala, Sweden
Sponsors and Collaborators
Uppsala University
Principal Investigator: Haile Mahteme, MD PhD Dept of Surgical Sciences, University Hospital, Uppsala, Sweden
  More Information

Responsible Party: Haile Mahteme, MD PhD, Dept of Surgical Sciences, Section of Surgery, Uppsala University, Sweden Identifier: NCT00997633     History of Changes
Other Study ID Numbers: SPECT IK1991:5
Study First Received: October 16, 2009
Last Updated: October 16, 2009

Keywords provided by Uppsala University:
Intraperitoneal volume
peritoneal carcinomatosis
cytoreductive surgery
intraperitoneal chemotherapy

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms processed this record on May 25, 2017